SCHEMBL578354

SCHEMBL578354

Oc1oc2ccccc2c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
NQO1 P15559 7/20 0.52
CYP3A4 P08684 3/20 0.52
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 2/20 0.52
TP53 P04637 2/20 0.52
MAPK1 P28482 2/20 0.52
ABCB11 O95342 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 1/20 0.52
PDE4D Q08499 1/20 0.52
PCSK7 Q16549 1/20 0.52
GPR35 Q9HC97 1/20 0.52
CA12 O43570 3/20 0.48
CA9 Q16790 3/20 0.48
TOP1 P11387 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28410509 0.98 KDM4E (0.52) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL1180659 0.82 KDM4E (0.62) KDM4ECYP3A4ALDH1A1MEN1KMT2A
SCHEMBL29155467 0.76 AHR (0.46) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL20657033 0.76 KDM4E (0.55) KDM4ENQO1CYP3A4ALDH1A1KMT2A
SCHEMBL28961807 0.76 KDM4E (0.50) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL744133 0.76 KDM4E (0.60) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL29872 0.75 KDM4E (0.69) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL29379994 0.75 KDM4E (0.69) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL7737431 0.75 KDM4E (0.69) KDM4ENQO1CYP3A4ALDH1A1MEN1
SCHEMBL11778619 0.73 PTPN1 (0.49) KDM4ENQO1CYP3A4ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109549918-B Ophthalmic medicine composition, ophthalmic medicine box and medical application thereof 沈阳兴齐眼药股份有限公司 2023-05-23 CN claimed
CN-219001692-U Balloon device containing estrogen for preventing uterine cavity adhesion 深圳市罗湖区妇幼保健院 2023-05-12 CN claimed
CN-114432231-A Ophthalmic pharmaceutical composition, ophthalmic medicine box and medical application thereof 沈阳兴齐眼药股份有限公司 2022-05-06 CN claimed
EP-2751160-B1 EPOXY RESINS WITH HIGH THERMAL STABILITY AND TOUGHNESS HUNTSMAN ADV MAT AMERICAS INC (US) 2016-09-28 EP claimed
EP-2751160-A1 EPOXY RESINS WITH HIGH THERMAL STABILITY AND TOUGHNESS Huntsman Advanced Materials Americas LLC (US) 2014-07-09 EP claimed
US-20140069583-A1 Epoxy Resins With High Thermal Stability and Toughness HUNTSMAN ADVANCED MATERIALS AMERICAS LLC 2014-03-13 US claimed
CN-102199138-B Preparation method for 6, 7-di-substituted-2, 3 dihydrobenzofuran SHANGHAI DESANO PHARMACEUTICALS HOLDING CO LTD 2013-06-12 CN claimed
WO-2012158363-A1 EPOXY RESINS WITH HIGH THERMAL STABILITY AND TOUGHNESS HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) 2012-11-22 WO claimed
CN-102199138-A Preparation method for 6, 7-di-substituted-2, 3 dihydrobenzofuran SHANGHAI DESANO PHARMACEUTICALS HOLDING CO LTD 2011-09-28 CN claimed
US-20040022834-A1 Pharmaceutical oxan preparation PIERRE FABRE MEDICAMENT (FR) 2004-02-05 US claimed
US-4564691-A Process for preparing substituted 2,3-dihydrobenzofuran ENICHIMICA SECONDARIA S.P.A. (IT) 1986-01-14 US claimed
EP-0127208-A1 Process for preparing substituted 2,3-dihydrobenzofuran ENICHIMICA SECONDARIA S.p.A. (IT) 1984-12-05 EP claimed
US-20250019374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF SYGNATURE DISCOVERY LIMITED (GB) 2025-01-16 US disclosed
EP-4430038-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2024-09-18 EP disclosed
US-20240293482-A1 COMPOSITIONS AND METHODS FOR TREATING BIOFILMS, INFECTIONS AND PERIODONTITIS ETHEIM BIOTICS LLC (US) 2024-09-05 US disclosed
CN-118525016-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2024-08-20 CN disclosed
US-6620953-B1 Complexing dimethylbis(2-methyl-4,5-benzoindenyl)silane with transition metal compounds such as 2,4-di-tert-butylphenoxide, zirconium monochloride, to form polymerization catalysts BASSELL POLYOLEFINE GMBH (DE) 2003-09-16 US disclosed
US-5262418-A Laxatives, gastrointestinal disorders TANSSEN PHARMACEUTICA N.V. (BE) 1993-11-16 US disclosed
US-4014906-A Process for the manufacture of anthraquinone compounds CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed
US-3969372-A 2,3-Dihydro-3,3-dimethyl-2,5-benzofurandiol from isobutyraldehyde and benzoquinone EASTMAN KODAK COMPANY (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN5, PTPN1, PTPN3 KDM4E 505/4885NQO1 2387/4885CYP3A4 3604/4885
US-20040022834-A1 Pharmaceutical oxan preparation OXA1L, OSTC, OTC KDM4E 2740/4885NQO1 305/4885CYP3A4 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.